Bank of Nova Scotia
BNS
The Toronto-Dominion Bank
TD
Royal Bank of Canada
RY
Bank of Montreal
BMO
Canadian Imperial Bank of Commerce
CM
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.